Skip to main content
Premium Trial:

Request an Annual Quote

Third Wave s Golden Goodbye Kiss


When the planned $300 million merger between Third Wave Technologies and PE Biosystems collapsed earlier this year, one little-noticed side effect involved an $8 million payment that Third Wave had made to buy back rights to its technology.

In 1997 Third Wave and cytokine specialist Endogen signed a five-year deal giving Endogen certain exclusive development rights to Third Wave’s Invader genotyping technology. But PE Biosystems would have none of that. As a condition of the merger PE ordered Third Wave to buy back the two-and-a-half years’ worth of rights, which Third Wave promptly did for $2 million in cash and a $6 million promissory note.

When the merger blew up, not only was Third Wave out the $8 million, but also there was no longer an Endogen deal.

At least not for Third Wave: In mid-1999 Sweden’s Perbio Sciences acquired Endogen for $13.5 million. But Third Wave’s $8 million payment effectively reduced the net purchase price to $5.5 million. Perbio president Mats Fischier pronounces the transaction “favorable.” Guess so.

The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.